Novocure seeks approval after pancreatic cancer wearable scores at Phase III
Novocure is seeking regulatory approval in the US, EU, Japan and other key markets after the Phase III PANOVA-3 pancreatic…
Latest News
-
-
Customer-centricity takes the spotlight during clinical transformation
Alcon decided to take a platform-based approach to support its clinical transformation efforts when parent company Novartis decided to spin…
-
Ondine accelerates pivotal antimicrobial trial after $11m financing
Ondine Biomedical will initiate a Phase III trial of its light-activated antimicrobial technology to reduce healthcare-associated infections (HAIs) early after…
-
CSA Medical completes enrolment in chronic bronchitis trial
CSA Medical has completed enrolment in its SPRAY-CB trial (NCT03893370) for patients with chronic obstructive pulmonary disease (COPD) with chronic…
-
How will a Labour government support the UK clinical trials industry?
On 4 July 2024, the people of the UK took to the polls and made their voice heard, voting for…
-
AI database to bolster research for GLP1-RAs as precision medicines
An AI database that utilises real-world data (RWD) could help sponsors decide where to next investigate glucagon-like peptide-1 receptor agonists…
-
Further positive results reported from Sebela’s investigational IUD
Sebela Women's Health has announced it has further positive results in a pivotal Phase III open-label study of the investigational…
-
AstraZeneca hopes to make clinical trial operations carbon-negative by 2030
AstraZeneca has big plans to become carbon-negative by 2030, including collecting human samples obtained in clinical trials. The company is…
-
Push for more NHS organisations to get involved in clinical research
There is hope that everyone in the UK's National Health Service (NHS) to get involved in clinical research, said professor…
-
Headband to treat mild and moderate Alzheimer’s disease to be trialled
Electro Cellular Healthcare Solutions (ECHS) is trialling a wearable headband device to treat patients with mild to moderate Alzheimer’s disease…
